###### What is already known on this topic?

-   Children presenting with severe acute malnutrition (SAM) are usually also severely stunted suggesting that their malnutrition is often not only acute.

-   Several studies have reported minimal average height/length-for-age z-score (HAZ) gain during recovery from SAM despite intense nutritional support and weight gain.

-   A threshold of wasting recovery before linear catch-up growth has previously been proposed.

###### What this study adds?

-   Despite an insignificant change in mean HAZ subgroups of children gained or lost HAZ beyond that predicted by regression to the mean.

-   No threshold of wasting recovery preceding linear catch-up growth was observed.

-   More active prevention and treatment of illness following SAM treatment may provide opportunities to improve linear growth.

Introduction {#s1}
============

Stunting (defined as height/length-for-age z-score (HAZ) ≤2 using WHO 2006 growth reference standards) is the most prevalent form of undernutrition: 151 million children under 5 years old were stunted in 2017.[@R1] A Sustainable Development Goal has been set by the United Nations to reduce the proportion of children who are stunted worldwide by 40% by 2025.[@R5] More than 90% of stunted children live in Africa and Asia.[@R1] In Kenya, 26% of under-5s were stunted in 2014,[@R6] with wide subnational variation, ranging from 15% in central Kenya to 46% on the coast.[@R6] Stunting is considered to be a result of chronic malnutrition, exacerbated by frequent infections, especially diarrhoea.[@R8] In resource-poor countries, it is estimated that approximately a fifth of stunting occurs in utero and continues up to 2 years of age.[@R10] Being stunted is associated with reduced cognitive development and adult productivity, adverse maternal reproductive outcomes and risks of non-communicable diseases in adulthood.[@R3] Despite being globally recognised as the most frequent form of undernutrition, stunting is often overlooked in the clinic because length/height is not routinely measured in health facilities in affected countries, some communities consider short stature as 'normal', and specific effective interventions are lacking.[@R3]

An overview of published clinical trials among children with severe acute malnutrition (SAM) reveals that they are also usually severely stunted, thus their malnutrition is not only acute (listed in online [supplementary table 1](#SP1){ref-type="supplementary-material"}).[@R14] The main target of treatment and nutritional rehabilitation of complicated SAM is to increase body weight and/or mid-upper arm circumference (MUAC).[@R16] It might therefore be expected that such intervention would also impact on linear growth. However, clinical trials of treatment for SAM in Asia and Africa demonstrate that children with SAM have little or no change in average HAZ following treatment (online [supplementary table 1](#SP1){ref-type="supplementary-material"}).[@R19] In one study of 369 predominantly oedematous Jamaican children recovering from severe malnutrition, Walker *et al* observed that in a subgroup who were more severely stunted and mostly non-oedematous, weight gain preceded catch-up in linear growth and proposed that reaching a threshold of weight-for-height/length z-scores (WHZ) of −1.3 was required before linear catch-up growth could begin.[@R24]
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We therefore evaluated linear growth and its associated factors among HIV-uninfected children enrolled in a multicentre randomised clinical trial during recovery from complicated SAM and followed up for 12 months.[@R23]

Patients and methods {#s2}
====================

Study design and setting {#s2a}
------------------------

We performed a secondary analysis of data from a double-blinded, randomised placebo-controlled trial (ClinicalTrials.gov NCT00934492).[@R23] The original trial was designed to determine the efficacy of daily co-trimoxazole prophylaxis in reducing postdischarge mortality among children with complicated SAM. The intervention had no overall effect on linear growth.[@R23]

The trial recruited children from paediatric wards of four Kenyan hospitals while receiving treatment for complicated SAM: Mbagathi County Hospital (Nairobi), Coast General Hospital (Mombasa), Kilifi County Hospital and Malindi Subcounty Hospital.

Study population {#s2b}
----------------

The original trial recruited children aged 2--59 months, hospitalised with complicated SAM defined as: MUAC \<11 cm for children \<6 months, MUAC \<11.5 cm for children 6--59 months, or oedema at any age.[@R23] Children were excluded if they had positive HIV rapid antibody test, because they were already recommended to receive daily co-trimoxazole prophylaxis, or had known hypersensitivity to co-trimoxazole. Children were enrolled into the trial after the initial 'stabilization' phase of SAM inpatient treatment and caregiver consent was provided.[@R18] Participants were scheduled to attend clinic visits monthly after study enrolment up to month 6 and thereafter, every 2 months up to month 12, giving a total of 1-year follow-up.

Study outcomes {#s2c}
--------------

The main study outcome was change in HAZ between study enrolment and month 12. The exposures of interest were age, gender, recruitment site, gain in weight-for-age z-score (WAZ), WHZ and MUAC, clinical variables at enrolment, randomisation arm and illness episodes occurring during follow-up.

Data sources and measurements {#s2d}
-----------------------------

At enrolment, clinical history, disease signs and sociodemographic data were collected. During enrolment and at every scheduled visit, length (or height for children ≥24 months old), weight and MUAC were measured and documented.[@R23]

During follow-up, hospital readmissions and illness episodes treated as an outpatient were prospectively documented. Study staff visited the homes of children failing to attend scheduled visits. During these home visits, vital status was assessed and MUAC measured, but weight and height were not measured because of the measurement equipment required.

Study size {#s2e}
----------

We used data from all (n=1169) participants who (1) survived, (2) remained in the 1-year follow-up, and (3) had their HAZ measured at study end.

Statistical methods {#s2f}
-------------------

All analyses were conducted using Stata V.15.1 (StataCorp, College Station, TX, USA). HAZ, WHZ and WAZ were calculated using the 2006 WHO growth reference. Change in HAZ between enrolment and month 12 was categorised into three groups: minimal change in HAZ of −0.25 to 0.25; loss of HAZ \>0.25; and gain in HAZ \>0.25 according to Walker and Golden.[@R24] We hypothesised that gain or loss of HAZ may be associated with different baseline factors and these were thus analysed as separate outcomes using the minimal change group as the reference. To evaluate the effect of regression to the mean (RTM), gain or loss of HAZ was adjusted for the difference between individuals' HAZ values and the group mean HAZ value at enrolment.[@R25] We used backwards stepwise multinomial logistic regression to determine the features associated with either loss or gain, retaining variables with p\<0.1, and reported adjusted coefficients transformed to relative risk ratios with p\<0.05 in the final model. We also performed a sensitivity analysis to explore the factors associated with HAZ loss or gain from baseline to month 12 among stunted children at baseline only. To determine the extent to which overall changes in weight, WAZ, WHZ and MUAC were associated with HAZ changes during follow-up, we calculated the Spearman's rank correlation coefficient after excluding children with oedema at enrolment, and examined other factors associated with change in HAZ using multinomial logistic regression.

To look for evidence that a curve indicating inflection or threshold characterised the relationship between changes in HAZ and changes in weight, WAZ, WHZ and MUAC rather than a straightforward linear relationship, we performed multivariable fractional polynomial regression (MFPR) adjusted for age, gender, study site and randomisation arm. Regression models based on fractional polynomial curves (powers of −2, −1, −0.5, 0, 0.5, 1, 2, 3) were compared with a linear model by testing for difference in deviance using the STATA *mfp* command. The fractional polynomial term was retained if there was significant difference in deviance from the linear model.[@R26]

To test the threshold proposed by Walker and Golden, we compared linear growth among children, including those with oedema at enrolment, above and below the threshold of WHZ −1.3 or more after 1 month, using a Wilcoxon rank-sum test.[@R24]

Results {#s3}
=======

The original trial enrolled 1778 children. We excluded 609 (34%) children; (257 (14%) died, 56 (3.1%) were lost to follow-up, 36 (2.0%) voluntarily withdrew and 260 (15%) had no HAZ measured at month 12). Thus, 1169 children were included in this analysis, median (IQR) age at enrolment was 11 (7 -- 17) months, and 565 (48%) were girls ([table 1](#T1){ref-type="table"}). Mean (SD) HAZ at enrolment was −2.87 (1.6). Overall, 358 (31%), 290 (25%) and 521 (44%) were not stunted, moderately and severely stunted, respectively (online [supplementary table 2](#SP1){ref-type="supplementary-material"} and online [supplementary figure 1](#SP1){ref-type="supplementary-material"}). Baseline stunting was associated with older age, female sex, recruitment hospital, reported low birth weight, presence of oedema and lower MUAC (online [supplementary tables 3 and 4](#SP1){ref-type="supplementary-material"}). Children who were excluded had similar enrolment characteristics, but a higher frequency of postdischarge illness episodes (under follow-up events in [table 1](#T1){ref-type="table"}).

###### 

Study participants' profile at time of enrolment and follow-up

                                                    All participants in primary trial (n=1778)   Participants assessed at month 12 and included in the secondary analysis (n=1169)
  ------------------------------------------------- -------------------------------------------- -----------------------------------------------------------------------------------
  Demographics at study enrolment                                                                
   Age in months, median (IQR)                      11 (7--16)                                   11 (7--17)
   Sex, female                                      875 (49)                                     565 (48)
   Born prematurely\*                               221 (12)                                     141 (12)
   Born underweight†                                362 (20)                                     229 (20)
   Main caregiver-biological mother                 1661 (93)                                    1088 (93)
   Randomised to co-trimoxazole prophylaxis         887 (50)                                     597 (51)
   Currently breast feeding                         1092 (61)                                    712 (61)
   Recruitment hospital                                                                          
    Kilifi County Hospital                          151 (8.5)                                    114 (9.8)
    Coast General Hospital                          849 (48)                                     542 (46)
    Malindi Subcounty Hospital                      271 (15)                                     202 (17)
    Mbagathi County Hospital                        507 (29)                                     311 (27)
  Nutritional status at study enrolment                                                          
   Oedema                                           300 (17)                                     210 (18)
   MUAC (cm), mean±SD                               10.6±1.1                                     10.6±1.0
   HAZ, mean±SD                                     −2.87±1.7                                    −2.87±1.6
   WAZ, mean±SD                                     −3.99±1.0                                    −3.96±1.0
   WHZ, mean±SD                                     −3.34±1.3                                    −3.32±1.2
   Haemoglobin (g/dL), mean±SD                      9.9±2.2                                      9.8±2.3
  Index admission diagnosis                                                                      
   Index admission with diarrhoea                   1021 (57)                                    679 (58)
   Index admission with severe pneumonia            656 (37)                                     404 (35)
   Index admission with tuberculosis                67 (3.8)                                     45 (3.9)
   Index admission with clinical signs of rickets   230 (13)                                     139 (12)
    Index admission with other comorbidities‡       97 (5.5)                                     66 (5.7)
  Follow-up events                                                                               
   Outpatient treatment for diarrhoea               653 (37)                                     329 (28)
   Outpatient treatment for pneumonia               716 (40)                                     275 (24)
   Outpatient treatment for another diagnosis§      547 (31)                                     387 (33)
   Hospital readmission for diarrhoea               218 (12)                                     102 (8.7)
   Hospital readmission for severe pneumonia        308 (17)                                     159 (14)
   Hospital readmission for another diagnosis§      236 (13)                                     96 (8.2)
   Died                                             257 (14)                                     --
   Withdrawn or loss to follow-up                   92 (5.2)                                     --

The results are n (%) except when specified.

WAZ and WHZ exclude children with oedema. Outpatient treatment comprised any treatment offered to the participant either during scheduled or unscheduled follow-up visits.

\*Gestational age \<37 weeks.

†Birth weight \<2500 g.

‡Comorbidity assessed at study enrolment including 5 sickle cell, 15 heart disease, 38 cerebral palsy, 3 epilepsy and 5 children with both cerebral palsy and epilepsy.

§Diagnoses of malaria, tuberculosis, sepsis, meningitis, measles, anaemia, and urinary tract infection and skin/soft tissue infection.

HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.

The largest monthly change in HAZ was from enrolment to month 1, a drop (SD) of 0.20 (0.5) z-scores (online [supplementary table 3](#SP1){ref-type="supplementary-material"}, online [supplementary figures 2 and 3](#SP1){ref-type="supplementary-material"}). After month 1, mean (SD) HAZ rose to −2.94 (1.4) at month 4 and thereafter plateaued to month 12. In contrast, during the first month, WAZ, WHZ and MUAC (cm) had their largest gains (online [supplementary table 5](#SP1){ref-type="supplementary-material"} and online [supplementary figure 2](#SP1){ref-type="supplementary-material"}).

At month 12, the mean (SD) HAZ was −2.88 (1.4), a change (SD) of −0.006 (1.1) since enrolment ([figure 1](#F1){ref-type="fig"} and online [supplementary table 5](#SP1){ref-type="supplementary-material"}). WAZ, WHZ and MUAC at month 12 had increased (SD) since enrolment by 1.46 (1.2), 1.94 (1.5) and 2.83 (1.4) cm, respectively ([figure 1](#F1){ref-type="fig"}, online [supplementary table 5](#SP1){ref-type="supplementary-material"} and online [supplementary figure 2](#SP1){ref-type="supplementary-material"}).

![Dot plot of change between study enrolment and month 12 in HAZ, WHZ, WAZ and MUAC (cm). The dashed line (Y=0) indicates no change; the horizontal red bars are the respective anthropometry mean change. HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.](archdischild-2018-315641f01){#F1}

Of the 1169 children, 262 (23%) had minimal change in HAZ from enrolment to month 12, while 472 (40%) lost \>0.25 and 435 (37%) gained \>0.25 z-scores (online [supplementary table 6](#SP1){ref-type="supplementary-material"}). Most children (744/1169; 64%) were in the same HAZ category (severely, moderately or not stunted) at month 12 as they had been at study enrolment (online [supplementary table 2](#SP1){ref-type="supplementary-material"} and online [supplementary figure 1](#SP1){ref-type="supplementary-material"}).

Features associated with changes in HAZ {#s3a}
---------------------------------------

The youngest and oldest children had the largest change in HAZ, giving age a skewed U-shaped association (p\<0.001 compared with a linear fit) (online [supplementary figure 4](#SP1){ref-type="supplementary-material"}). Age \<12 months was associated with losing HAZ in the univariate analysis (online [supplementary table 7](#SP1){ref-type="supplementary-material"}).

In the multivariate analyses, losing HAZ was associated with postdischarge outpatient treatment for diarrhoea, hospital readmission for diarrhoea and for severe pneumonia, and randomisation to co-trimoxazole prophylaxis after adjusting for RTM ([table 2](#T2){ref-type="table"}). Gain in HAZ was associated with the caregiver not being the child's biological mother, reported preterm birth and randomisation to co-trimoxazole after adjusting for RTM ([table 2](#T2){ref-type="table"}). Children born preterm had lower HAZ at enrolment than other participants (p\<0.001), and their HAZ increased (SD) during the 1-year period to −3.04 (1.3), which was not significantly different from the other children (−2.85 (1.4)) (p=0.06) (online [supplementary figure 5](#SP1){ref-type="supplementary-material"}). In a sensitivity analysis, the factors associated with HAZ gain or loss among children who were already stunted at enrolment were found to be similar to those of the overall cohort (online [supplementary table 8](#SP1){ref-type="supplementary-material"}).

###### 

Factors associated with loss or gain of HAZ during the 1-year follow-up

  Demographics at study enrolment                 Lost at least 0.25 HAZ\*   Gained at least 0.25 HAZ\*                                 
  ----------------------------------------------- -------------------------- ---------------------------- ------- ------ -------------- ------
  Main caregiver not the biological mother        --                         --                           --      2.42   1.19 to 4.92   0.02
  Randomised to co-trimoxazole prophylaxis        0.70                       0.51 to 0.96                 0.03    0.72   0.52 to 0.99   0.05
  Born prematurely†                               --                         --                           --      1.97   1.18 to 3.28   0.01
  Follow-up illness events                                                                                                              
   Outpatient treatment for diarrhoea             1.68                       1.15 to 2.44                 0.007   --     --             --
   Readmission to hospital for diarrhoea          1.91                       1.02 to 3.55                 0.04    --     --             --
   Readmission to hospital for severe pneumonia   1.90                       1.12 to 3.22                 0.02    --     --             --

\*Compared with children with minimal change in HAZ (±0.25Z). HAZ difference is the difference between HAZ at month 12 and at study enrolment.

†Gestational age \<37 weeks. Relative risk ratios are computed using multinomial logistic regression with minimal HAZ change (−0.25 to 0.25Z) as the reference and adjusted for regression to the mean. All the factors examined in the multivariate multinomial logistic regression are reported on univariate analysis (online [supplementary table 5](#SP1){ref-type="supplementary-material"}). Here only factors with a p value \<0.05 are presented; p values are from multivariable multinomial logistic regression.

HAZ, height/length-for-age z-score; RRR, relative risk ratio.

Changes in weight, WAZ and MUAC between enrolment and month 12 had strong positive correlation with absolute change in HAZ, while change in WHZ had weak correlation ([table 3](#T3){ref-type="table"}). Overall, there was no evidence from the MFPR analyses of an inflection in the association between change in HAZ up to month 12 and change in weight, WAZ, WHZ or MUAC ([figure 2](#F2){ref-type="fig"}).

![Scatter plots of change in HAZ with: (A) change in weight (kg) (p=0.25), (B) changes in WAZ (p=0.11), (C) change in WHZ (p=0.07), and (D) change in MUAC (cm) (p=0.24) with fitted fractional polynomial curves (95% CI). P values are from comparisons of model deviance between multiple fractional polynomial regression and linear regression models. HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.](archdischild-2018-315641f02){#F2}

###### 

Multivariable analysis of association between HAZ change and changes in weight, WAZ, WHZ and MUAC during 1-year follow-up

  Change between study enrolment and month 12   Correlation coefficient†   Lost at least 0.25 HAZ\*   Gained at least 0.25 HAZ\*                                   
  --------------------------------------------- -------------------------- -------------------------- ---------------------------- --------- ------ -------------- ---------
  Change in weight per  kg                      0.55                       0.46                       0.39 to 0.56                 \<0.001   2.15   1.82 to 2.54   \<0.001
  Change in WAZ per z-score                     0.61                       0.44                       0.35 to 0.55                 \<0.001   2.19   1.77 to 2.71   \<0.001
  Change in WHZ per z-score                     0.15                       0.80                       0.69 to 0.92                 0.002     1.10   0.95 to 1.27   0.19
  Change in MUAC per cm                         0.46                       0.69                       0.60 to 0.80                 \<0.001   1.46   1.28 to 1.68   \<0.001

\*Compared with children with minimal change in HAZ (±0.25Z).

†Spearman's rank correlation coefficient.

‡Adjusted for co-trimoxazole randomisation arm, child carer, born premature (\<37 weeks), height-for-age at study enrolment, outpatient treatment for diarrhoea and readmission during follow-up for diarrhoea. Relative risk ratios are computed using multinomial logistic regression with minimal HAZ change (−0.25 to 0.25Z) as the reference. P values from multivariable multinomial logistic regression.

HAZ, height/length-for-age z-score; MUAC, mid-upper arm circumference; RRR, relative risk ratio; WAZ, weight-for-age z-score; WHZ, weight-for-height/length z-score.

At month 1,275 (24%) children were above the threshold proposed by Walker and Golden[@R24] of WHZ −1.3. These children had fewer baseline comorbidities, were less wasted and more stunted at enrolment than children below the threshold (online [supplementary table 9](#SP1){ref-type="supplementary-material"}). Between enrolment and month 1, children lost approximately 0.2 HAZ irrespective of reaching WHZ −1.3 or not (p=0.40) ([figure 3](#F3){ref-type="fig"} and online [supplementary table 9](#SP1){ref-type="supplementary-material"}). Linear growth between months 1 and 3 was greater in children who were above WHZ −1.3 than children below this threshold at month 1 (p\<0.001). However, from month 3 to month 12 there were no differences in absolute values or changes in HAZ between these two groups (p=0.23) ([figure 3](#F3){ref-type="fig"} and online [supplementary table 9](#SP1){ref-type="supplementary-material"}).

![HAZ trajectory between participants below and above WHZ −1.3 at month 1 of follow-up. The dashed vertical line show time point when the WHZ used to group the participants was taken (month 1); anthropometry was not collected at months 7, 9 and 11; the plotted data are means and 95% CI. HAZ, height/length-for-age z-score; WHZ, weight-for-height/length z-score.](archdischild-2018-315641f03){#F3}

Discussion {#s4}
==========

Despite inpatient, medical and nutritional treatment for complicated SAM and subsequent outpatient therapeutic feeding, active follow-up to 1 year with access to extra care and referral for specialist services where needed by the study team, there was no significant average increase in HAZ. This was despite rapid weight and MUAC gain.

Previous trials that monitored children recovering from SAM in Africa have similarly demonstrated catch-up in weight but not in linear growth.[@R20] In a community-based study in Nepal, wasted children gained weight but not height, suggesting wasted children experience weight growth at the expense of growing length.[@R28] However, severely malnourished children in Jamaica experienced increased growth in both weight and height, although linear growth tended to occur later than weight growth.[@R29]

Overall, an increase in WHZ was not associated with positive linear growth in our study and there was no evidence of a threshold WAZ or WHZ gain required for a linear growth catch-up. When we examined a previously proposed threshold of wasting[@R24] in relation to linear growth, we found a short period of accelerated linear growth among a subset of children with very different baseline characteristics, suggesting that early linear growth response predominantly depends on baseline status, such as the presence or absence of comorbidities.

Whereas having episodes of diarrhoea during follow-up was associated with linear growth deficit, length was not gained by not having diarrhoea. This concurs with results from a pooled analysis of data from seven studies in the general community that found diarrhoea was associated with long-term decrease in linear growth.[@R31] Previous studies have also reported other infectious diseases such as malaria and respiratory illnesses may be associated with linear growth faltering.[@R14] We found an association with hospital admission for severe pneumonia, but the occurrence of malaria was too rare to be included in our analyses separately. However, in a multicountry birth cohort in low/middle-income countries, while diarrhoea was not a risk factor for poor linear growth, but presence of higher enteropathogen load in non-diarrhoea stools was associated with poor length growth.[@R32]

Although not examined in this study, environmental enteric dysfunction (EED) common in resource-poor countries has been suggested as additional factor impacting on linear growth.[@R34] EED is characterised by systematic inflammation of the small intestine, which is more frequent among children with SAM and likely to increase metabolic demands, altered nutrient processing by the microbiota and absorption, thereby affecting linear growth.[@R35] Providing 81 Jamaican malnourished children with metronidazole to treat small intestinal bacterial overgrowth in addition to a high energy nutritional supplement improved both linear and weight growth compared with the supplement only.[@R37] Metronidazole is now being tested in a large (n=2000) multicentre clinical trial among children with SAM (ISRCTN18051843).

The parent trial intervention, co-trimoxazole prophylaxis had a stabilising effect on HAZ, reducing both gain and loss. The mechanism for this is unclear but may reflect potential multiple effects of co-trimoxazole on infection, as well as on the gut microbiota involved in nutrient processing and absorption. Similarly, co-trimoxazole was associated with increased diarrhoea in the original trial, but reduced malaria, skin and urinary tract infections.[@R23]

Unlike findings from previous studies, after adjusting for other factors, age was not independently associated with HAZ changes.[@R38] Children born prematurely had greater linear growth than their term peers in this study, reaching a similar HAZ to other children after 12 months of follow-up. However, typically preterm neonates may not fully catch up in length with full-term infants.[@R41] Children not cared by their biological parents were mostly under the care of children's homes where nutritional and emotional care may have promoted linear growth (sometimes this was initiated at the index admission by the hospitals' social services when absence of a home carer was identified).

Pooled  and meta-analyses of numerous interventions to improve linear growth have demonstrated marginal efficacy.[@R34] Bhutta *et al* predicted that implementing all the evidence-based nutritional interventions would only reduce stunting by 20% globally.[@R42] However, a trial in Ecuador has recently demonstrated that introduction of daily eggs during the weaning period (6--9 months) reduced stunting by 47%.[@R43] These results are encouraging, suggesting that protein quality over a prolonged period may be important and should be tested in different settings, including following treatment for SAM.

Strengths and limitations {#s4a}
-------------------------

We systematically followed children for 1 year after inpatient treatment for complicated SAM, a longer period than most SAM studies.[@R19] Being a clinical trial meant a higher level of clinical care and opportunities for linear growth gain that may not exist in routine care. We adjusted for the study intervention allocation in the multivariable regression analysis. A limitation of this study was selection bias because we could only analyse data from participants with length measurement at month 12. Although excluded children had similar baseline characteristics, those without a month 12 measurement because of death, withdrawal or not physically attending this visit may have been more likely to have linear growth deficit than included children because they were more often ill during follow-up (under follow-up events in [table 1](#T1){ref-type="table"}).

Conclusion {#s5}
==========

Overall, intensive treatment and nutritional rehabilitation did not resolve stunting among children with SAM. Although reaching a previously proposed threshold of absolute WHZ of −1.3 was associated with increased short-term linear growth, this was seen in a subset of children who were less wasted, more stunted and with less comorbidity at enrolment. Interventions that prevent illness and improve dietary quality over a longer period may provide opportunities to improve linear growth following SAM.
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